CHIP variants are often discovered incidentally in liquid biopsy testing, but is plasma cell-free DNA reliable when CHIP variants are the desired finding? 🩸@BloodAdvances @AlexBickMDPhD 🧵1/12

Happy Halloween from the Bick lab!

We are delighted to share that this work is now published in Genetics in Medicine Open (@TheACMG)! We hope to deploy our algorithm to identify people for whom HbA1c is inadequate for their diabetes management. Many thanks to co-authors (see thread) and participants @AlexBickMDPhD

Seeing this in real time at VUMC where 1 in 5 cath lab patients have CHIP. We're building care pathways but standardization across centers would help. Curious what others are doing for longitudinal follow-up. @MichaelR21 @pnatarajanmd @AlexBickMDPhD

Excited to share our latest publication in @BloodVTH We report an ANKRD26 VUS with thrombosis & CCUS—illustrating the real-world challenges of interpreting germline variants in myeloid NGS testing. A call for better frameworks & richer variant databases. @AlexBickMDPhD Limited

We are excited to share our new paper – “IL-17RA signalling modifies cardiovascular disease risk in JAK2 clonal haematopoiesis” published in European Heart Journal  🧬🫀 1/n https://t.co/8vETgTdyG5 @AlexBickMDPhD @yash_pershad @VUMCDiscoveries @ehj_ed

We had a big presence at the @AGBT conference, w/ great sessions by our CMO @personalizedmed, Dr. Tara Dutka, @AlexBickMDPhD and Dr. Leann Redman discussing All of Us, #AI, #Nutrition & #PrecisionMedicine 🧬 Thanks to all who attended! #AGBTPH25

🚨📢❗So proud and excited to share our latest work, "Clonal Hematopoiesis Dynamics and Evolutionary Fitness During Cancer Treatment Impact Clinical Outcomes", now available: https://t.co/EQu4Ilx2Hf🧵

Longitudinal analysis of the LoDoCo2 clinical trial suggests that colchicine blunts TET2 CHIP expansion possibly mediated by reductions in IL-6! These results add to a growing body of evidence that colchicine and IL-6R blockers may be beneficial for CHIP-associated CVD...

“Are there existing drugs that we can repurpose or new drugs we can develop to stop cancer progression before it starts?” @AlexBickMDPhD is leading research at @VUMChealth that could answer those questions.

The lab's first sim pub of #ESC2025 is now online in @JACCJournals #JACC ! https://t.co/iTZGizylr2 Led by 🇧🇪⭐️ @daniel_ezt , we examined clonal hematopoiesis (CHIP) 🩸 & cardiovascular 🫀 outcomes in older women 👵 using deep targeted 🧬 sequencing in the @WHIStudy 👇 (1/X)

Important evidence to take into consideration when evaluating and conducting #clonalhematopoiesis / #CHIP research! Told ya so?

Thank you ⁦@CD_AACR⁩ for highlighting our recent work led by ⁦@jieliu09⁩. Wonderful collaborative effort with ⁦@pnatarajanmd⁩ ⁦@AlexBickMDPhD⁩ among others!

Biobank scale #CHIP calls are a great first pass... but to establish the true strength of disease associations we need to use deep targeted sequencing.

The future of #RUNX1FPD research is here! In Session 5 of our 9th Annual Virtual RUNX1 Scientific Conference, early-career investigators, post-docs & grad students present their cutting-edge work in our Poster Session — featuring @OHSUNews, @OHSUKnight, @VUMChealth, @PennMed &

Are you planning to apply for faculty positions in North America this Fall? Our team of researchers have synthesized 3 years of applicant survey data to create a dashboard to allow assistant professor candidates to see where they stand. https://t.co/zgKXcD0mD1

A new preprint led by @AlexBickMDPhD, @madduri, and @yash_pershad, with co-authors including @LabAgarwal and RRP’s @EricsonKatrin, uses a closed-loop #AI system to identify and validate therapeutic targets for RUNX1-FPD. One of these targets, mTOR, supports earlier findings by

Germline genetic variation has been linked to both hematologic cancer and clonal hematopoiesis. But does germline variation influence the likelihood of CH progressing to cancer? And if so, why? We tackle these questions here in @NatureGenet https://t.co/oICxxJHhI3

Delighted to collaborate on this study led by @jieliu09 @KellyLBolton describing how germline genetic variation influences the trajectory of clonal hematopoiesis to hematologic malignancy https://t.co/D1aYY9C6rE @NatureGenet

Very excited to share our paper investigating the evolution of therapy-related CH in myeloma pts treated w/ or w/o LEN. Can we predict the risk for second blood cancer in myeloma pts? Grateful for the collaboration with @UCCancerCenter myeloma program. https://t.co/CsqA3M6iji